- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.12. | Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease | ||
| 15.12. | How rare-disease teams can fine-tune COAs to bridge meaningful change and measurable progress | ||
| 12.12. | Arcus cancels work on Gilead-partnered cancer combo after trial setback | ||
| 12.12. | Praxis tees up another approval filing; Geron turns to layoffs | ||
| 11.12. | AC Immune posts positive data for Parkinson's immunotherapy | ||
| 11.12. | Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer | ||
| 11.12. | Lilly's three-pronged drug puts obesity field 'on notice' | ||
| 11.12. | Crapo, Cassidy propose enhanced ACA subsidy alternative | ||
| 11.12. | Prolynx banks $70M for longer-lasting obesity drugs | ||
| 10.12. | FDA approves first drug in National Priority Voucher program | ||
| 10.12. | A former Roivant spinout bets on AI-designed drugs for immune conditions | ||
| 09.12. | Novartis notches another win for drug acquired in MorphoSys deal | ||
| 09.12. | Pfizer dips into China for another try at an obesity pill | ||
| 09.12. | J&J's 'remarkable' Tecvayli data support earlier use in multiple myeloma | ||
| 08.12. | Terns drug shows potential to challenge Novartis' blockbuster leukemia treatment | ||
| 08.12. | Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay | ||
| 08.12. | Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar | ||
| 08.12. | How digital companion apps unlock value across the drug lifecycle | ||
| 08.12. | At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma | ||
| 05.12. | RFK Jr.'s hand-picked panel questions childhood vaccine schedule | ||
| 05.12. | Hemophilia gene therapies are struggling on the market, even as innovation soars | ||
| 05.12. | Praxis soars higher; Bristol Myers' CAR-T therapy wins broader use | ||
| 04.12. | CDC panel again postpones vote on newborns' hepatitis B shot | ||
| 04.12. | An Arch-backed biotech raises $53M to fight neurodegeneration | ||
| 04.12. | 12 former FDA chiefs blast Prasad's move to toughen vaccine standards |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .